Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology has disclosed Receivables - Accured across 5 years of filings, most recently posting $5.7 million for Q1 2024.

• Receivables - Accured for Q1 2024 came in at $5.7 million, up 171.43% year-over-year; the trailing twelve-month figure through Mar 2024 was $5.7 million (up 171.43% YoY), and the FY2023 annual result was $4.0 million, up 60.0% from the prior year.
• Receivables - Accured came in at $5.7 million for Q1 2024 at Vir Biotechnology, up from $4.0 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $5.7 million in Q1 2024 to a low of $600000.0 in Q2 2021.
• The 5-year median for Receivables - Accured is $1.8 million (2022), against an average of $2.1 million.
• Peak annual rise in Receivables - Accured reached 250.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Vir Biotechnology's Receivables - Accured stood at $800000.0 in 2020, then surged by 37.5% to $1.1 million in 2021, then soared by 127.27% to $2.5 million in 2022, then jumped by 60.0% to $4.0 million in 2023, then jumped by 42.5% to $5.7 million in 2024.
• The last three Receivables - Accured figures came in at $5.7 million (Q1 2024), $4.0 million (Q4 2023), and $2.9 million (Q3 2023), per Business Quant data.